A Study to Investigate the Effect of CYP2C19 Phenotype on the Pharmacokinetics of LY2216684 in Healthy Subjects.
Phase of Trial: Phase I
Latest Information Update: 01 Nov 2012
At a glance
- Drugs Edivoxetine (Primary) ; Quinidine
- Indications Depressive disorders; Major depressive disorder
- Focus Pharmacogenomic; Pharmacokinetics
- Sponsors Eli Lilly
- 10 Jun 2017 Biomarkers information updated
- 01 Oct 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 18 Sep 2012 Planned end date changed from 1 Sep 2012 to 1 Nov 2012 as reported by ClinicalTrials.gov.